Public Citizen chief hopes to "influence" FDA

Curious about Sid Wolfe's new role as an advisory committee member at the FDA? Ed Silverman at Pharmalot interviewed the consumer activist about his hopes for influence at the agency. Report

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.